Aligos Therapeutics (NASDAQ:ALGS) Earns “Buy” Rating from HC Wainwright

Aligos Therapeutics (NASDAQ:ALGS)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $50.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 390.20% from the stock’s current price.

Aligos Therapeutics Trading Down 6.3%

ALGS opened at $10.20 on Friday. The firm has a market cap of $62.74 million, a P/E ratio of -0.52 and a beta of 2.79. Aligos Therapeutics has a 12 month low of $3.76 and a 12 month high of $46.80. The stock has a 50-day moving average of $9.13 and a 200 day moving average of $8.05.

Aligos Therapeutics (NASDAQ:ALGS) last released its earnings results on Wednesday, August 6th. The company reported ($1.53) earnings per share for the quarter, beating the consensus estimate of ($2.35) by $0.82. The firm had revenue of $0.97 million for the quarter, compared to the consensus estimate of $0.43 million. Aligos Therapeutics had a negative return on equity of 22.41% and a negative net margin of 2,337.24%. On average, research analysts forecast that Aligos Therapeutics will post -10.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Tower Research Capital LLC TRC boosted its holdings in Aligos Therapeutics by 2,073.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 652 shares of the company’s stock valued at $26,000 after purchasing an additional 622 shares during the last quarter. Northern Trust Corp purchased a new stake in shares of Aligos Therapeutics during the fourth quarter worth $205,000. Golden State Wealth Management LLC boosted its holdings in shares of Aligos Therapeutics by 100.0% during the 1st quarter. Golden State Wealth Management LLC now owns 5,348 shares of the company’s stock worth $44,000 after purchasing an additional 2,674 shares during the last quarter. XTX Topco Ltd purchased a new position in Aligos Therapeutics during the second quarter worth about $100,000. Finally, AlphaQuest LLC purchased a new position in shares of Aligos Therapeutics during the 1st quarter worth $130,000. 60.43% of the stock is owned by institutional investors and hedge funds.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).